Other Titles
The Lived Experiences of Adults with Sickle Cell Disease Deciding Curative Therapies [Title Slide]
Abstract
Purpose: Hematopoietic stem cell transplant (HSCT) and gene therapy (GT) are experimental therapies used to cure the inherited blood disorder, Sickle Cell Disease (SCD). These curative SCD therapies have been shown to decrease pain, improve organ function, and improve health-related quality of life (HRQOL). Relatively little is known about the experience of deciding whether to cure SCD from the patient’s perspective. The purpose of this study is to explore the lived experiences of adults living with SCD considering curative therapies.
Methods: This study took place at a large urban academic medical center that cares for adults living with SCD. Adults with a diagnosis of SCD and over 18 years old were eligible for this study. Participants who were experiencing an acute complication of SCD (i.e., vaso-occlusive crisis, stroke, or acute chest syndrome), were pregnant, or had mental disabilities were excluded. Participants had to be fluent in speaking and reading English. Using a descriptive phenomenological approach, semi-structured interviews using questions derived from the literature were used to collect the data. Participants were interviewed for 60 minutes describing their experience of deciding curative treatments. Audio recordings where transcribed and analyzed using Giorgi’s five-step method.
Results: Nine adults (Male (n= 4) and Female (n= 5)) ages 25 to 37 years old with SCD were interviewed. Eight participants had Hemoglobin SS (HbSS) disease (n= 8) and one had Hemoglobin SC (HbSC) disease (n= 1). Participants were Nigerian/Black (n=1), African American (n =2), Caribbean-American/Black (n = 1), Latinx/Black (n= 2), Hispanic (n= 1), Latino (n=1), Caribbean/Black (n=1). Five themes with subthemes emerged: (1) The never-ending rollercoaster of uncertainty in SCD (subthemes: physical uncertainty, emotional uncertainty and spiritual uncertainty), (2) hospital feeling as a second home (subthemes: hospital feeling as a second home, nuanced support systems, and a catalyst for important decisions), (3) the powerful influence of the provider (subthemes: exclusion, a dream deferred, and new information is music to my ears) (4) changing the trajectory of the past in pursuit of new beginnings (subthemes: changing the trajectory of the past, and the pursuit of new beginnings (5) going the distance to access a cure.
Conclusion: Deciding to cure SCD focuses on the biopsychosocial complexities of the disease and requires deep deliberation. Past experiences of living with SCD have deep implications when deciding. The length of time involved in the decision-making, the disappointments, and constant changes or postponements throughout their lives were found to drain participants’ emotional drive. Clinical nurses and nursing leadership must have the skills and expertise to be change agents and support the needs of adults with SCD. The complexity of SCD curative therapies suggests the nurse to be well-educated, supportive, resourceful, and present in decision making. Interventions must be patient-centered. It is imperative that SCD-specific care is integrated in to nursing education. Nursing education should work toward building a diverse workforce who are capable of handling the complex care management of SCD.
Notes
Presenter notes available in attached slide deck. To see the notes in Adobe Acrobat, go to Tools > Comment or look at your Layers Panel. If the notes were saved as comments or layers, you can toggle them visible.
References:
Mekelenkamp, H., Smiers, F., Camp, N., Stubenrouch, F., Lankester, A., & De Vries, M. (2021). Decision making for hematopoietic stem cell transplantation in pediatric, adolescent, and young adult patients with a hemoglobinopathy—Shared or not? Pediatric Blood & Cancer, 68(9). https://doi.org/10.1002/pbc.29099
Nardo-Marino, A., Brousse, V., & Rees, D. (2020). Emerging therapies in sickle cell disease. British Journal of Haematology, 190(2), 149-172.
Rotin, L. E., Viswabandya, A., Kumar, R., & Kuo, K. H. M. (2020). Allogeneic hematopoietic stem cell transplant versus gene therapy in sickle cell disease: Updated results from a systematic review. Blood, 136, 11-12. doi:10.1182/blood-2020-141309.
Schulz, G. L., Kelly, K. P., Holtmann, M., & Armer, J. M. (2021). Navigating decisional conflict as a family when facing the decision of stem cell transplant for a child or adolescent with sickle cell disease. Patient Education and Counseling, 104(5), 1086–1093. https://doi.org/10.1016/j.pec.2020.10.011
Sharma, A., Young, A., Carroll, Y., Darji, H., Li, Y., Mandrell, B. N., Nelson, M. N., Owens, C. L., Irvine, M., Caples, M., Jerkins, L. P., Unguru, Y., Hankins, J. S., & Johnson, L. (2023). Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers. Pediatric Blood & Cancer, 70(6), e30319. https://doi.org/10.1002/pbc.30319
Sinha, C. B., Bakshi, N., Ross, D., Loewenstein, G., & Krishnamurti, L. (2021). Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer, 68(1). https://doi.org/10.1002/pbc.28749
Holdford, D., Vendetti, N., Sop, D. M., Johnson, S., & Smith, W. R. (2021). Indirect Economic Burden of Sickle Cell Disease. Value in Health, 24(8), 1095–1101. https://doi.org/10.1016/j.jval.2021.02.014
Giorgi, A. (2009). The descriptive phenomenological method in psychology. Duquesne University Press.
Kanter, J., Tisdale, J. F., Mapara, M. Y., Kwiatkowski, J. L., Krishnamurti, L., Chen, R., . . . Walters, M. C. (2020). Improvements in health-related quality of life for patients treated with LentiGlobin for sickle cell disease (bb1111) gene therapy. Blood, 136, 10. doi:10.1182/blood-2020-136193
National Academies of Sciences, Engineering, and Medicine 2020. Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action. Washington, DC: The National Academies Press. https://doi.org/10.17226/25632.
Sigma Membership
Delta Zeta, Omega Kappa
Type
Presentation
Format Type
Text-based Document
Study Design/Type
Phenomenology
Research Approach
Qualitative Research
Keywords:
Sickle Cell Anemia Treatment, Adults, Patients' Attitudes, Sickle Cell Anemia, Patient Decision Making
Recommended Citation
Jacobs, Charleen, "The Lived Experience of Deciding Curative Treatments for Adults With Sickle Cell Disease" (2026). International Nursing Research Congress (INRC). 9.
https://www.sigmarepository.org/inrc/2024/presentations_2024/9
Conference Name
35th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Singapore
Conference Year
2024
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record. All permission requests should be directed accordingly and not to the Sigma Repository. All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Review Type
Abstract Review Only: Reviewed by Event Host
Acquisition
Proxy-submission
Date of Issue
2026-11-10
The Lived Experience of Deciding Curative Treatments for Adults With Sickle Cell Disease
Singapore
Purpose: Hematopoietic stem cell transplant (HSCT) and gene therapy (GT) are experimental therapies used to cure the inherited blood disorder, Sickle Cell Disease (SCD). These curative SCD therapies have been shown to decrease pain, improve organ function, and improve health-related quality of life (HRQOL). Relatively little is known about the experience of deciding whether to cure SCD from the patient’s perspective. The purpose of this study is to explore the lived experiences of adults living with SCD considering curative therapies.
Methods: This study took place at a large urban academic medical center that cares for adults living with SCD. Adults with a diagnosis of SCD and over 18 years old were eligible for this study. Participants who were experiencing an acute complication of SCD (i.e., vaso-occlusive crisis, stroke, or acute chest syndrome), were pregnant, or had mental disabilities were excluded. Participants had to be fluent in speaking and reading English. Using a descriptive phenomenological approach, semi-structured interviews using questions derived from the literature were used to collect the data. Participants were interviewed for 60 minutes describing their experience of deciding curative treatments. Audio recordings where transcribed and analyzed using Giorgi’s five-step method.
Results: Nine adults (Male (n= 4) and Female (n= 5)) ages 25 to 37 years old with SCD were interviewed. Eight participants had Hemoglobin SS (HbSS) disease (n= 8) and one had Hemoglobin SC (HbSC) disease (n= 1). Participants were Nigerian/Black (n=1), African American (n =2), Caribbean-American/Black (n = 1), Latinx/Black (n= 2), Hispanic (n= 1), Latino (n=1), Caribbean/Black (n=1). Five themes with subthemes emerged: (1) The never-ending rollercoaster of uncertainty in SCD (subthemes: physical uncertainty, emotional uncertainty and spiritual uncertainty), (2) hospital feeling as a second home (subthemes: hospital feeling as a second home, nuanced support systems, and a catalyst for important decisions), (3) the powerful influence of the provider (subthemes: exclusion, a dream deferred, and new information is music to my ears) (4) changing the trajectory of the past in pursuit of new beginnings (subthemes: changing the trajectory of the past, and the pursuit of new beginnings (5) going the distance to access a cure.
Conclusion: Deciding to cure SCD focuses on the biopsychosocial complexities of the disease and requires deep deliberation. Past experiences of living with SCD have deep implications when deciding. The length of time involved in the decision-making, the disappointments, and constant changes or postponements throughout their lives were found to drain participants’ emotional drive. Clinical nurses and nursing leadership must have the skills and expertise to be change agents and support the needs of adults with SCD. The complexity of SCD curative therapies suggests the nurse to be well-educated, supportive, resourceful, and present in decision making. Interventions must be patient-centered. It is imperative that SCD-specific care is integrated in to nursing education. Nursing education should work toward building a diverse workforce who are capable of handling the complex care management of SCD.
Description
The experiences of adults living with sickle cell disease who are considering curative therapies like gene therapy and hematopoietic stem cell transplantation are not well described in the literature. The findings from this descriptive phenomenology research study and its implications for nursing research, education, and health policy will be discussed.
The presenter has authored a published article on this topic:
Jacobs-Mcfarlane, C. (2025). The lived experiences of adults with sickle cell disease deciding curative therapies: A descriptive phenomenological study. Western Journal of Nursing Research, 47(5), 384–394. https://doi.org/10.1177/01939459251321429